Blood Podcast

Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma

Mar 16, 2023
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 3min
2
Aesocytidine and HSPCs in MDS and CMML Patients
02:34 • 3min
3
Aesocytidine in MDS and CMML - A Review
05:31 • 3min
4
The Risk of VTE Prophylaxis in Glioma
08:08 • 4min
5
VTE in Glioma and Other Cancers - Part 3
11:42 • 3min
6
The Prognostic Impact of P32 Deletion in Newly Diagnosed Multiple Myeloma
14:31 • 2min
7
The Impact of 1P32 Deletion in Newly Diagnosed Multiple Myeloma
16:36 • 4min